Factors associated with weight gain in people with type 2 diabetes starting on insulin

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2108-2113

  Balkau, Beverley ^a,b   Home, Philip D ^c   Vincent, Maya ^d   Marre, Michel ^e   Freemantle, Nick ^f  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d SANOFI   (France)

^e INSERM   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; GERMANY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PORTUGAL; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WEIGHT CHANGE; WEIGHT GAIN; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84904988779     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-3010     Document Type: Article

References (20)

1. Holman RR, Paul SK, Bethel M.A., Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
2. Ray KK, Seshasai SR, Wijesuriya S, et al Effect ofintensive control of glucose oncardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
3. The Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia 2009; 52: 2470]. Diabetologia 2009; 52: 2288-2298
4. Home P, Naggar NE, Khamseh M, et al An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1 chieve study. Diabetes Res Clin Pract 2011; 94: 352-363
5. Inzucchi SE, Bergenstal RM, Buse J.B., et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
6. Holman RR, Thorne KI, Farmer A.J., et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730
7. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011; 13: 1008-1019
8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
9. Freemantle N, Balkau B, Home PD A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013; 15: 1120-1127
10. Freemantle N, Balkau B, Danchin N., et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012; 14: 901-909
11. UK Prospective Study of Therapies of Maturity-Onset Diabetes. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983; 24: 404-411
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control withsul-phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
13. Diamant M, Van Gaal L, Stranks S, et al Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243
14. Gerstein HC, Bosch J, Dagenais G.R., et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
15. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care 2001; 24: 1849-1850
16. Home P, Malek R, Prusty V., Latif ZA, Haddad J. Impact of insulin detemir on weight change in relation to baseline BMI: observations from the A 1chieve Study (Abstract). Diabetes 2013; 62: A246
17. Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab 2011; 13: 823-831
18. Idris I, Pillai A, Fernando D.J., Thomson G., Tate H. Responders to insulin therapy at 18 months in adults with newly diagnosed diabetes: which insulin regimen? Diabet Med 2013; 30: e95-e100
19. van Dieren S., Czernichow S, Chalmers J., et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012; 14: 464-469
20. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258